WDFY4 Antibody

Code CSB-PA747798LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human prostate cancer using CSB-PA747798LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human appendix tissue using CSB-PA747798LA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) WDFY4 Polyclonal antibody
Uniprot No.
Target Names
WDFY4
Alternative Names
WDFY4 antibody; C10orf64 antibody; KIAA1607WD repeat- and FYVE domain-containing protein 4 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human WD repeat- and FYVE domain-containing protein 4 protein (1-322AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The WDFY4 Antibody (Product code: CSB-PA747798LA01HU) is Non-conjugated. For WDFY4 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA747798LB01HU WDFY4 Antibody, HRP conjugated ELISA
FITC CSB-PA747798LC01HU WDFY4 Antibody, FITC conjugated
Biotin CSB-PA747798LD01HU WDFY4 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The WDFY4 polyclonal antibody is raised in rabbits against the peptide corresponding to amino acid residues 1-322 of the human WDFY4 protein. It occurs as an unconjugated IgG. It is purified by protein G and reaches up to 95% in purity. And it only reacts with human WDFY4 protein. Validations of this antibody have been done in ELISA and IHC assays. The target protein WDFY4 is required for the cross-presentation of cell- and bacterial-associated antigens. It also plays a key role in cDC1-mediated viral and tumor immunity.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a critical role in the regulation of cDC1-mediated cross-presentation of viral and tumor antigens in dendritic cells. Mechanistically, acts near the plasma membrane and interacts with endosomal membranes to promote endosomal-to-cytosol antigen trafficking. Plays also a role in B-cell survival through regulation of autophagy.
Gene References into Functions
  1. A significantly increased risk for RA associated with the WDFY4 rs7097397 AG genotype. PMID: 24549174
  2. rs877819 SNP in WDFY4 may be associated with systemic lupus erythematosus by reduced binding of YY1 and downregulating WDFY4 expression. PMID: 22972472
  3. Genetic variants in ETS1 and WDFY4 were found to be associated with systemic lupus erythematosus, in the Asian population studied. PMID: 20169177
Subcellular Location
Early endosome. Endoplasmic reticulum.
Database Links

HGNC: 29323

OMIM: 613316

KEGG: hsa:57705

STRING: 9606.ENSP00000320563

UniGene: Hs.287379

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*